PYXS
Pyxis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.76
+4.76%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.71
From 52W high−67.04%
Volume1.02M
Market cap$146.80M
P/E (TTM)—
P/S (TTM)13.3x
Div yield—
Key dataOct 19, 2026
Open
$1.71
From 52W high
−67.04%
Volume
1.02M
Market cap
$146.80M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
P/E (TTM)
—
RSI (14)
28.6
MomentumView details →
1D Return
+4.76%
YTD Return
+53.29%
SummaryUpdated Jun 1, 2026
Pyxis Oncology, Inc. (NASDAQ:PYXS) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts. The company went public in October 2021 and focuses on developing innovative cancer therapies through two primary technological approaches: immune-oncology treatments and antibody drug conjugates. As a preclinical company, Pyxis is in the early stages of drug development, with its product candidates still undergoing laboratory and early clinical testing before potentially advancing to human trials and eventual commercialization.
Similar companies
Latest newsMore news →
Pyxis Oncology, Inc. commenced a registered public offering of common stock, pre-funded warrants, and accompanying common warrants.21d agoPyxis Oncology appointed John Flavin as Lead Independent Director, effective September 4, 2026.42d agoPyxis Oncology appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026.42d ago